Longitudinal Study of Markers of Oxidative Capacity and Type 2 Diabetes

氧化能力和 2 型糖尿病标志物的纵向研究

基本信息

  • 批准号:
    8235034
  • 负责人:
  • 金额:
    $ 44.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-03-30 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In the United States, over 40% of adults have diabetes or pre-diabetes according to recently published NHANES data. The consequences of this burden are well-known. Compared to their non-diabetic counterparts, Americans with diabetes are at much greater risk to die and to develop vascular and infectious complications. The prevalence of type 2 diabetes has increased as a direct result of the exponential rise in the number of overweight and obese individuals in the United States. Although the mechanisms linking obesity with type 2 diabetes are uncertain, increased adiposity is closely tied to insulin resistance, a key physiologic derangement connected to the development of type 2 diabetes. Insulin resistance is also associated with older age and decreased physical activity, well-established antecedents of type 2 diabetes. Despite the strength of the evidence linking these risk factors with insulin resistance and subsequent type 2 diabetes, the underlying mechanism driving insulin resistance is not well understood. Accumulating evidence suggests, however, that decreased capacity to metabolize glucose via oxidative processes (i.e. mitochondrial dysfunction) plays a fundamental role in the development of insulin resistance. For example, a number of small animal and clinical studies have shown that genetic mutations, oxidative stress, abnormal mitochondrial morphology, diminished oxidative gene expression, decreased oxidative phosphorylation, and low aerobic capacity are associated with obesity, insulin resistance, and type 2 diabetes. Despite the emerging consensus regarding the importance of energy homeostasis in metabolic disorders, there are no feasible methods for assessing mitochondrial function in large population-based studies or in clinical populations. Recent evidence suggests, however, that blood and urine levels of molecules involved in glucose metabolism (e.g. lactate, alanine, succinate, and 1- ketoglutarate) are indicators of mitochondrial dysfunction. Therefore, these molecules may be useful tools in the investigation of the relationship between mitochondrial dysfunction and metabolic disorders. Based on this evidence, we hypothesize that mitochondrial dysfunction, assessed by measuring molecules involved in glucose metabolism and energy production is associated with type 2 diabetes and other states of elevated glucose. To test this hypothesis, we propose to measure these factors in the Atherosclerosis Risk in Communities (ARIC) Study, an on-going investigation of atherosclerosis among approximately 15,000 adults from 4 U.S. communities. Our goal is to assess the association of lactate, alanine, succinate, and 1- ketoglutarate with states of elevated glucose and incident type 2 diabetes. If our hypothesis is correct, our study should: 1) confirm the importance of mitochondrial dysfunction in diabetes 2) offer the first set of tools for assessing mitochondrial dysfunction in an epidemiologic or clinical setting, 3) identify risk factors for decreased oxidative capacity and 4) identify genetic variants associated with mitochondrial dysfunction. PUBLIC HEALTH RELEVANCE: The prevalence of type 2 diabetes has increased markedly due to the exponential rise in obesity. Despite its importance, the underlying mechanisms responsible for type 2 diabetes are still poorly understood. In this study, our goal is to examine the role that decreased capacity to metabolize glucose via oxidative processes plays in diabetes in a population-based study consisting of approximately 15,000 people from 4 U.S. communities. If successful, this work could lead to new ways to assess risk for diabetes and its complications in the clinic and to novel approaches for diabetes prevention and treatment.
描述(申请人提供):根据最近公布的NHANES数据,在美国,超过40%的成年人患有糖尿病或糖尿病前期。这一负担的后果是众所周知的。与非糖尿病患者相比,患有糖尿病的美国人死亡以及发生血管和感染性并发症的风险要大得多。美国超重和肥胖人数的指数增长直接导致了2型糖尿病患病率的增加。尽管肥胖与2型糖尿病之间的联系机制尚不确定,但肥胖增加与胰岛素抵抗密切相关,胰岛素抵抗是与2型糖尿病发展相关的一种关键生理紊乱。胰岛素抵抗也与高龄和体力活动减少有关,这是2型糖尿病的既定先兆。尽管有强有力的证据将这些危险因素与胰岛素抵抗和随后的2型糖尿病联系起来,但推动胰岛素抵抗的潜在机制尚不清楚。然而,越来越多的证据表明,通过氧化过程代谢葡萄糖的能力下降(即线粒体功能障碍)在胰岛素抵抗的发展中起着重要作用。例如,许多小动物和临床研究表明,基因突变、氧化应激、线粒体形态异常、氧化基因表达减弱、氧化磷酸化降低和有氧能力低下与肥胖、胰岛素抵抗和2型糖尿病有关。尽管关于能量平衡在代谢紊乱中的重要性的共识正在形成,但在大规模基于人群的研究中或在临床人群中评估线粒体功能还没有可行的方法。然而,最近的证据表明,血液和尿液中与葡萄糖代谢有关的分子水平(如乳酸、丙氨酸、琥珀酸和1-酮戊二酸)是线粒体功能障碍的指标。因此,这些分子可能是研究线粒体功能障碍与代谢紊乱之间关系的有用工具。基于这一证据,我们假设线粒体功能障碍,通过测量参与葡萄糖代谢和能量产生的分子进行评估,与2型糖尿病和其他血糖升高状态有关。为了验证这一假设,我们建议在社区动脉粥样硬化风险(ARIC)研究中衡量这些因素,该研究正在对来自美国4个社区的约15,000名成年人进行动脉粥样硬化调查。我们的目标是评估乳酸、丙氨酸、琥珀酸和1-酮戊二酸与血糖升高和2型糖尿病的关系。如果我们的假设是正确的,我们的研究应该:1)确认线粒体功能障碍在糖尿病中的重要性;2)提供第一套工具,在流行病学或临床环境中评估线粒体功能障碍;3)确定氧化能力降低的风险因素;4)确定与线粒体功能障碍相关的基因变异。 公共卫生相关性:由于肥胖率呈指数上升,2型糖尿病的患病率显著增加。尽管它很重要,但导致2型糖尿病的潜在机制仍然知之甚少。在这项研究中,我们的目标是在一项由来自美国4个社区的约15,000人组成的基于人群的研究中,检查通过氧化过程代谢葡萄糖的能力降低在糖尿病中所起的作用。如果成功,这项工作可能导致在临床上评估糖尿病及其并发症的风险的新方法,以及糖尿病预防和治疗的新方法。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Association of blood lactate with carotid atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study.
  • DOI:
    10.1016/j.atherosclerosis.2013.02.014
  • 发表时间:
    2013-05
  • 期刊:
  • 影响因子:
    5.3
  • 作者:
    Shantha, Ghanshyam Palamaner Subash;Wasserman, Bruce;Astor, Brad C.;Coresh, Josef;Brancati, Fredrick;Sharrett, A. Richey;Young, J. Hunter
  • 通讯作者:
    Young, J. Hunter
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFERY HUNTER YOUNG其他文献

JEFFERY HUNTER YOUNG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFERY HUNTER YOUNG', 18)}}的其他基金

Longitudinal Study of Markers of Oxidative Capacity and Type 2 Diabetes
氧化能力和 2 型糖尿病标志物的纵向研究
  • 批准号:
    8053347
  • 财政年份:
    2010
  • 资助金额:
    $ 44.34万
  • 项目类别:
Longitudinal study of markers of oxidative capacity and type 2 diabetes
氧化能力和 2 型糖尿病标志物的纵向研究
  • 批准号:
    7777433
  • 财政年份:
    2010
  • 资助金额:
    $ 44.34万
  • 项目类别:
GENES AND SEVERE HYPERTENSION AMONG AFRICAN AMERICANS
非裔美国人的基因和严重高血压
  • 批准号:
    7378778
  • 财政年份:
    2005
  • 资助金额:
    $ 44.34万
  • 项目类别:
GENES AND SEVERE HYPERTENSION AMONG AFRICAN AMERICANS
非裔美国人的基因和严重高血压
  • 批准号:
    7200748
  • 财政年份:
    2005
  • 资助金额:
    $ 44.34万
  • 项目类别:
GENES AND SEVERE HYPERTENSION AMONG AFRICAN AMERICANS
非裔美国人的基因和严重高血压
  • 批准号:
    7378831
  • 财政年份:
    2005
  • 资助金额:
    $ 44.34万
  • 项目类别:
Genes and Severe Hypertension among African Americans
非裔美国人的基因和严重高血压
  • 批准号:
    7044597
  • 财政年份:
    2003
  • 资助金额:
    $ 44.34万
  • 项目类别:
Genes and Severe Hypertension among African Americans
非裔美国人的基因和严重高血压
  • 批准号:
    7044702
  • 财政年份:
    2003
  • 资助金额:
    $ 44.34万
  • 项目类别:
HYPERTENSION AMONG AFRICAN-AMERICANS
非裔美国人的高血压
  • 批准号:
    6642082
  • 财政年份:
    2002
  • 资助金额:
    $ 44.34万
  • 项目类别:
HYPERTENSION AMONG AFRICAN-AMERICANS
非裔美国人的高血压
  • 批准号:
    7105483
  • 财政年份:
    2002
  • 资助金额:
    $ 44.34万
  • 项目类别:
HYPERTENSION AMONG AFRICAN-AMERICANS
非裔美国人的高血压
  • 批准号:
    6916302
  • 财政年份:
    2002
  • 资助金额:
    $ 44.34万
  • 项目类别:

相似海外基金

Targeting aerobic glycolysis via hexokinase 2 inhibition in Natural Killer T cell lymphomas
通过抑制己糖激酶 2 靶向自然杀伤 T 细胞淋巴瘤中的有氧糖酵解
  • 批准号:
    23K07830
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Developing Late Metal Catalytic Systems for Aerobic Partial Oxidation of Alkanes
开发烷烃有氧部分氧化的后金属催化系统
  • 批准号:
    2247667
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
    Standard Grant
Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults
同时进行有氧运动和认知训练可预防高危老年人的阿尔茨海默病
  • 批准号:
    10696409
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
Precision Medicine in Alzheimer’s Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses
阿尔茨海默病的精准医学:使用 AT(N) 生物标志物优化有氧健身反应的适应性运动及其作用机制的 SMART 试验
  • 批准号:
    10581973
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
MIND Foods and Aerobic Training in Black Adults with HTN: An ADRD Prevention Pilot RCT (MAT)
MIND 食品和患有 HTN 的黑人成人的有氧训练:ADRD 预防试点随机对照试验 (MAT)
  • 批准号:
    10585366
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
Investigating the physical and chemical controls on aerobic methane oxidation
研究好氧甲烷氧化的物理和化学控制
  • 批准号:
    2241873
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
    Standard Grant
Effect of aerobic exercise-induced sleep changes on arterial stiffness associated with postprandial hyperglycemia.
有氧运动引起的睡眠变化对与餐后高血糖相关的动脉僵硬度的影响。
  • 批准号:
    23K10645
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pro-Resolving Inflammatory Mediators in Neurovascular Gains in Aerobic Training; a phase 2, double-blind, randomized placebo-controlled trial (PRIMiNG-AT2)
有氧训练中促进神经血管增益的炎症介质的消除;
  • 批准号:
    485524
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
    Operating Grants
Regulators of Photoreceptor Aerobic Glycolysis in Retinal Health and Disease
视网膜健康和疾病中光感受器有氧糖酵解的调节因子
  • 批准号:
    10717825
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
Supporting Aging through Green Exercise (SAGE): Comparing the cognitive effects of outdoor versus indoor aerobic exercise in older adults with mild cognitive impairment: A proof-of-concept randomized controlled trial
通过绿色运动支持老龄化 (SAGE):比较户外与室内有氧运动对患有轻度认知障碍的老年人的认知效果:概念验证随机对照试验
  • 批准号:
    495185
  • 财政年份:
    2023
  • 资助金额:
    $ 44.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了